Phase 3 Trials
Retatrutide
Triple Agonist
An experimental triple-hormone-receptor agonist targeting GLP-1, GIP, and Glucagon receptors, currently producing record-breaking trial data.
The Next Evolution
Retatrutide adds glucagon receptor agonism to the mix, which directly increases energy expenditure (calorie burning) while simultaneously suppressing appetite. Phase 2 trials demonstrated up to 24% body weight loss.
Available via Prescription
Retatrutide is a core component of the View Weight Loss.
View Protocol Options